Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.
暂无分享,去创建一个
M. Laakso | M. Hanefeld | S. Haulon | B. Staels | G. Chinetti | C. Zawadzki | W. Leonhardt | C. Koehler | T. Temelkova-Kurktschiev | A. Kubaszek
[1] R. Evans,et al. A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .
[2] Johan Auwerx,et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.
[3] J. Pankow,et al. Regarding "Testing for population subdivision and association in four case-control studies". , 2002, American journal of human genetics.
[4] Q. Ren,et al. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. , 2001, The Journal of clinical endocrinology and metabolism.
[5] Christopher K. Glass,et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.
[6] K. Clément,et al. The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes , 2000, International Journal of Obesity.
[7] Eric S. Lander,et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes , 2000, Nature Genetics.
[8] M. Laakso,et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. , 1999, The Journal of clinical endocrinology and metabolism.
[9] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[10] T. Kadowaki,et al. The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes , 2000 .
[11] C. Glass,et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .
[12] H. Häring,et al. The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects , 1999, Diabetologia.
[13] J. Auwerx,et al. The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene* , 1997, The Journal of Biological Chemistry.
[14] T. Jørgensen,et al. Studies of the Pro12Ala polymorphism of the ppar-γ gene in the Danish MONICA cohort: Homozygosity of the Ala allele confers a decreased risk of the Insulin Resistance syndrome , 2002 .
[15] Andrew C. Li,et al. Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .
[16] T. Temelkova-Kurktschiev,et al. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals , 1998, Diabetologia.
[17] B. Spiegelman,et al. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.
[18] Evaluation of arteriosclerosis progression with ultrasonic biopsy and intima-media thickness measurements. , 1993, VASA. Zeitschrift fur Gefasskrankheiten.
[19] M. Kasuga,et al. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. , 2001, Diabetes.
[20] B. Spiegelman,et al. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.
[21] J. Auwerx,et al. Transcription, adipocyte differentiation, and obesity , 1996, Journal of Molecular Medicine.
[22] P. Libby,et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.
[23] J. Salonen,et al. Measurement of intima-media thickness of common carotid arteries with high-resolution B-mode ultrasonography: inter- and intra-observer variability. , 1991, Ultrasound in medicine & biology.
[24] Arno W. Hoes,et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.
[25] K. Lunetta,et al. Testing for population subdivision and association in four case-control studies. , 2002, American journal of human genetics.
[26] M. Jimenez-Linan,et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. , 1997, The Journal of clinical investigation.
[27] T Gustavsson,et al. Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. , 1991, Clinical physiology.
[28] V. Colantuoni,et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. , 1999, Diabetes.
[29] R. Kronmal,et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.
[30] M. Stumvoll,et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. , 2001, Diabetes.
[31] M. Yamauchi,et al. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. , 1998, The Journal of clinical endocrinology and metabolism.
[32] B. Staels,et al. Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.
[33] M. Jaye,et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.
[34] P Pignoli,et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.
[35] K. Umesono,et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] F. Collins,et al. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. , 2001, Diabetes.
[37] J. Auwerx,et al. Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus , 2000, International Journal of Obesity.
[38] K. Anderson,et al. White blood cell count and cardiovascular disease. Insights from the Framingham Study. , 1992, JAMA.
[39] B. Seed,et al. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.